Lexicon Pharmaceuticals (Nasdaq: LXRX) is set to host a comprehensive virtual webcast focused on LX9211, their innovative non-opioid therapeutic candidate for diabetic peripheral neuropathic pain (DPNP). The two-hour event, scheduled for January 28, 2025, will bring together company leadership and distinguished external experts to discuss this potential breakthrough treatment.
Leadership Presentations and Clinical Progress
The webcast will feature key presentations from Lexicon's senior management team, including CEO Mike Exton, PhD, Vice President of Clinical Development Suma Gopinathan, PhD, and Senior Vice President and Chief Medical Officer Craig Granowitz, MD, PhD. Their discussions will provide strategic insights into LX9211's development and its potential impact on DPNP treatment.
Of particular significance, the event precedes the anticipated release of topline data from the Phase 2b PROGRESS trial later this quarter, marking a crucial milestone in LX9211's clinical development journey.
Expert Panel Discussion
The event will be enriched by perspectives from leading authorities in diabetes care. Dr. Rodica Pop-Busui, the 2023 President for Medicine and Science at the American Diabetes Association and Jordan Schnitzer Chair in Diabetes at Oregon Health & Science University, will share her expertise. She will be joined by Dr. Steve Edelman, Professor of Medicine at the University of California San Diego and founder of Taking Control Of Your Diabetes (TCOYD).
Clinical Significance and Market Impact
The focus on a non-opioid treatment for DPNP is particularly timely, given the ongoing need for effective alternatives to current pain management options. Diabetic peripheral neuropathic pain represents a significant unmet medical need, affecting a substantial portion of patients with diabetes and often proving challenging to treat effectively with existing therapies.
The webcast will be accessible through Lexicon's investor relations website, with on-demand viewing available following the live event. Healthcare professionals, investors, and other stakeholders can register to participate in this comprehensive discussion of what could potentially represent a paradigm shift in neuropathic pain treatment.
